相似文献
1
Chemosensitivity and p53; new tricks by an old dog.
Breast Cancer Res. 2012 Nov 6;14(6):325. doi: 10.1186/bcr3326.
2
Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Biochim Biophys Acta. 2013 Mar;1830(3):2790-7. doi: 10.1016/j.bbagen.2012.12.004.
3
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Breast Cancer Res. 2012 Mar 15;14(2):R47. doi: 10.1186/bcr3147.
4
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.
5
Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Oncotarget. 2017 Jun 20;8(25):41227-41241. doi: 10.18632/oncotarget.17167.
6
p53 in breast cancer subtypes and new insights into response to chemotherapy.
Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005.
7
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.
8
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
JCI Insight. 2019 Feb 26;5(6):124092. doi: 10.1172/jci.insight.124092.
9
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12.
10
Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Biochim Biophys Acta. 2015 Feb;1850(2):401-10. doi: 10.1016/j.bbagen.2014.11.007. Epub 2014 Nov 12.
引用本文的文献
1
p53 Modulates Radiosensitivity in Head and Neck Cancers-From Classic to Future Horizons.
Diagnostics (Basel). 2022 Dec 5;12(12):3052. doi: 10.3390/diagnostics12123052.
2
Sulfonoquinovosyl diacylglyceride selectively targets acute lymphoblastic leukemia cells and exerts potent anti-leukemic effects in vivo.
Sci Rep. 2015 Jul 20;5:12082. doi: 10.1038/srep12082.
3
The multitude of molecular analyses in cancer: the opening of Pandora’s box.
Genome Biol. 2014;15(9):447. doi: 10.1186/s13059-014-0447-6.
本文引用的文献
1
p53 opens the mitochondrial permeability transition pore to trigger necrosis.
Cell. 2012 Jun 22;149(7):1536-48. doi: 10.1016/j.cell.2012.05.014.
2
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
Cancer Cell. 2012 Jun 12;21(6):793-806. doi: 10.1016/j.ccr.2012.04.027.
3
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence.
Cell. 2012 Jun 8;149(6):1269-83. doi: 10.1016/j.cell.2012.04.026.
4
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Breast Cancer Res. 2012 Mar 15;14(2):R47. doi: 10.1186/bcr3147.
5
Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.
Cell. 2011 May 13;145(4):571-83. doi: 10.1016/j.cell.2011.03.035.
6
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.
7
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.
Breast Cancer Res. 2011 Jan 20;13(1):R7. doi: 10.1186/bcr2811.
8
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.
Mol Cancer. 2010 Jul 1;9:173. doi: 10.1186/1476-4598-9-173.
9
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12.
10
Blinded by the Light: The Growing Complexity of p53.
Cell. 2009 May 1;137(3):413-31. doi: 10.1016/j.cell.2009.04.037.
Zotero 插件